Carbapenem Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Drug Class (Meropenem, Imipenem, Ertapenem), By Application (Urinary Tract Infections, Blood Stream Infections, Pneumonia, Intra-abdominal Infections, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Others), By Region and Competition, 2020-2030F
The Global Carbapenem Market, valued at USD 3.92 Billion in 2024, is projected to experience a CAGR of 4.85% to reach USD 5.21 Billion by 2030. Carbapenems are a critical class of broad-spectrum beta-lactam antibiotics, primarily reserved for treating severe bacterial infections, particularly those caused by multidrug-resistant pathogens. The market's expansion is fundamentally driven by the escalating global challenge of antimicrobial resistance, necessitating effective last-resort treatments for complex infections.
Key Market Drivers
The escalating challenge of antimicrobial resistance represents a profound impetus for the global carbapenem market. As pathogens develop mechanisms to evade conventional treatments, carbapenems, often serving as last-line therapies, become indispensable. This urgent need is dramatically underscored by the concerning rise in highly resistant organisms; according to the Centers for Disease Control and Prevention, in September 2025, a report in Annals of Internal Medicine revealed NDM-producing carbapenem-resistant Enterobacterales infections surged by more than 460% in the United States between 2019 and 2023.
Key Market Challenges
The diminishing pipeline of novel antibiotics poses a significant impediment to the growth of the Global Carbapenem Market. As bacterial pathogens continuously evolve and develop resistance to existing treatments, the lack of new and innovative carbapenem-class drugs, or alternative agents effective against carbapenem-resistant organisms, directly curtails market expansion. This absence of a robust development pipeline means that the efficacy lifespan of current carbapenems is shortened by the escalating challenge of antimicrobial resistance, leading to a reduced demand as their clinical utility wanes.
Key Market Trends
The increasing penetration of generic carbapenems fundamentally influences market dynamics, improving accessibility and affordability of these critical last-line antibiotics. This trend enables broader patient populations to receive necessary treatments, especially in regions with budget constraints. According to Medicines for Europe, in October 2024, generic medicines constituted 70% of all dispensed medicines in Europe, and over 90% in the United States and India.
Key Market Players
In this report, the Global Carbapenem Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Company Profiles: Detailed analysis of the major companies presents in the Global Carbapenem Market.
Available Customizations:
Global Carbapenem Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
Key Market Drivers
The escalating challenge of antimicrobial resistance represents a profound impetus for the global carbapenem market. As pathogens develop mechanisms to evade conventional treatments, carbapenems, often serving as last-line therapies, become indispensable. This urgent need is dramatically underscored by the concerning rise in highly resistant organisms; according to the Centers for Disease Control and Prevention, in September 2025, a report in Annals of Internal Medicine revealed NDM-producing carbapenem-resistant Enterobacterales infections surged by more than 460% in the United States between 2019 and 2023.
Key Market Challenges
The diminishing pipeline of novel antibiotics poses a significant impediment to the growth of the Global Carbapenem Market. As bacterial pathogens continuously evolve and develop resistance to existing treatments, the lack of new and innovative carbapenem-class drugs, or alternative agents effective against carbapenem-resistant organisms, directly curtails market expansion. This absence of a robust development pipeline means that the efficacy lifespan of current carbapenems is shortened by the escalating challenge of antimicrobial resistance, leading to a reduced demand as their clinical utility wanes.
Key Market Trends
The increasing penetration of generic carbapenems fundamentally influences market dynamics, improving accessibility and affordability of these critical last-line antibiotics. This trend enables broader patient populations to receive necessary treatments, especially in regions with budget constraints. According to Medicines for Europe, in October 2024, generic medicines constituted 70% of all dispensed medicines in Europe, and over 90% in the United States and India.
Key Market Players
- Menarini Group
- Pfizer Inc.
- Sun Pharmaceutical Industries Ltd
- Lupin Limited
- Kopran Limited
- Aurobindo Pharma Limited
- Daewoong Pharmaceuticals Co., Ltd.
- Shenzhen Haibin Pharmaceutical Co. Ltd.
- Merck & Co., Inc.
- Venus Remedies Ltd.
In this report, the Global Carbapenem Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
- Carbapenem Market, By Drug Class:
- Meropenem
- Imipenem
- Ertapenem
- Carbapenem Market, By Application:
- Urinary Tract Infections
- Blood Stream Infections
- Pneumonia
- Intra-abdominal Infections
- Others
- Carbapenem Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Others
- Carbapenem Market, By Region:
- North America
- United States
- Canada
- Mexico
- Europe
- France
- United Kingdom
- Italy
- Germany
- Spain
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- South America
- Brazil
- Argentina
- Colombia
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
Company Profiles: Detailed analysis of the major companies presents in the Global Carbapenem Market.
Available Customizations:
Global Carbapenem Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional market players (up to five).
1. PRODUCT OVERVIEW
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. RESEARCH METHODOLOGY
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. EXECUTIVE SUMMARY
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. VOICE OF CUSTOMER
5. GLOBAL CARBAPENEM MARKET OUTLOOK
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Drug Class (Meropenem, Imipenem, Ertapenem)
5.2.2. By Application (Urinary Tract Infections, Blood Stream Infections, Pneumonia, Intra-abdominal Infections, Others)
5.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Others)
5.2.4. By Region
5.2.5. By Company (2024)
5.3. Market Map
6. NORTH AMERICA CARBAPENEM MARKET OUTLOOK
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Drug Class
6.2.2. By Application
6.2.3. By Distribution Channel
6.2.4. By Country
6.3. North America: Country Analysis
6.3.1. United States Carbapenem Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Drug Class
6.3.1.2.2. By Application
6.3.1.2.3. By Distribution Channel
6.3.2. Canada Carbapenem Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Drug Class
6.3.2.2.2. By Application
6.3.2.2.3. By Distribution Channel
6.3.3. Mexico Carbapenem Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Drug Class
6.3.3.2.2. By Application
6.3.3.2.3. By Distribution Channel
7. EUROPE CARBAPENEM MARKET OUTLOOK
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Drug Class
7.2.2. By Application
7.2.3. By Distribution Channel
7.2.4. By Country
7.3. Europe: Country Analysis
7.3.1. Germany Carbapenem Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Drug Class
7.3.1.2.2. By Application
7.3.1.2.3. By Distribution Channel
7.3.2. France Carbapenem Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Drug Class
7.3.2.2.2. By Application
7.3.2.2.3. By Distribution Channel
7.3.3. United Kingdom Carbapenem Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Drug Class
7.3.3.2.2. By Application
7.3.3.2.3. By Distribution Channel
7.3.4. Italy Carbapenem Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Drug Class
7.3.4.2.2. By Application
7.3.4.2.3. By Distribution Channel
7.3.5. Spain Carbapenem Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Drug Class
7.3.5.2.2. By Application
7.3.5.2.3. By Distribution Channel
8. ASIA PACIFIC CARBAPENEM MARKET OUTLOOK
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Drug Class
8.2.2. By Application
8.2.3. By Distribution Channel
8.2.4. By Country
8.3. Asia Pacific: Country Analysis
8.3.1. China Carbapenem Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Drug Class
8.3.1.2.2. By Application
8.3.1.2.3. By Distribution Channel
8.3.2. India Carbapenem Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Drug Class
8.3.2.2.2. By Application
8.3.2.2.3. By Distribution Channel
8.3.3. Japan Carbapenem Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Drug Class
8.3.3.2.2. By Application
8.3.3.2.3. By Distribution Channel
8.3.4. South Korea Carbapenem Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Drug Class
8.3.4.2.2. By Application
8.3.4.2.3. By Distribution Channel
8.3.5. Australia Carbapenem Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Drug Class
8.3.5.2.2. By Application
8.3.5.2.3. By Distribution Channel
9. MIDDLE EAST & AFRICA CARBAPENEM MARKET OUTLOOK
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Drug Class
9.2.2. By Application
9.2.3. By Distribution Channel
9.2.4. By Country
9.3. Middle East & Africa: Country Analysis
9.3.1. Saudi Arabia Carbapenem Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Drug Class
9.3.1.2.2. By Application
9.3.1.2.3. By Distribution Channel
9.3.2. UAE Carbapenem Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Drug Class
9.3.2.2.2. By Application
9.3.2.2.3. By Distribution Channel
9.3.3. South Africa Carbapenem Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Drug Class
9.3.3.2.2. By Application
9.3.3.2.3. By Distribution Channel
10. SOUTH AMERICA CARBAPENEM MARKET OUTLOOK
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Drug Class
10.2.2. By Application
10.2.3. By Distribution Channel
10.2.4. By Country
10.3. South America: Country Analysis
10.3.1. Brazil Carbapenem Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Drug Class
10.3.1.2.2. By Application
10.3.1.2.3. By Distribution Channel
10.3.2. Colombia Carbapenem Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Drug Class
10.3.2.2.2. By Application
10.3.2.2.3. By Distribution Channel
10.3.3. Argentina Carbapenem Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Drug Class
10.3.3.2.2. By Application
10.3.3.2.3. By Distribution Channel
11. MARKET DYNAMICS
11.1. Drivers
11.2. Challenges
12. MARKET TRENDS & DEVELOPMENTS
12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments
13. GLOBAL CARBAPENEM MARKET: SWOT ANALYSIS
14. PORTER'S FIVE FORCES ANALYSIS
14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products
15. COMPETITIVE LANDSCAPE
15.1. Menarini Group
15.1.1. Business Overview
15.1.2. Products & Services
15.1.3. Recent Developments
15.1.4. Key Personnel
15.1.5. SWOT Analysis
15.2. Pfizer Inc.
15.3. Sun Pharmaceutical Industries Ltd
15.4. Lupin Limited
15.5. Kopran Limited
15.6. Aurobindo Pharma Limited
15.7. Daewoong Pharmaceuticals Co., Ltd.
15.8. Shenzhen Haibin Pharmaceutical Co. Ltd.
15.9. Merck & Co., Inc.
15.10. Venus Remedies Ltd.
16. STRATEGIC RECOMMENDATIONS
17. ABOUT US & DISCLAIMER
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. RESEARCH METHODOLOGY
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. EXECUTIVE SUMMARY
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. VOICE OF CUSTOMER
5. GLOBAL CARBAPENEM MARKET OUTLOOK
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Drug Class (Meropenem, Imipenem, Ertapenem)
5.2.2. By Application (Urinary Tract Infections, Blood Stream Infections, Pneumonia, Intra-abdominal Infections, Others)
5.2.3. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Others)
5.2.4. By Region
5.2.5. By Company (2024)
5.3. Market Map
6. NORTH AMERICA CARBAPENEM MARKET OUTLOOK
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Drug Class
6.2.2. By Application
6.2.3. By Distribution Channel
6.2.4. By Country
6.3. North America: Country Analysis
6.3.1. United States Carbapenem Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Drug Class
6.3.1.2.2. By Application
6.3.1.2.3. By Distribution Channel
6.3.2. Canada Carbapenem Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Drug Class
6.3.2.2.2. By Application
6.3.2.2.3. By Distribution Channel
6.3.3. Mexico Carbapenem Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Drug Class
6.3.3.2.2. By Application
6.3.3.2.3. By Distribution Channel
7. EUROPE CARBAPENEM MARKET OUTLOOK
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Drug Class
7.2.2. By Application
7.2.3. By Distribution Channel
7.2.4. By Country
7.3. Europe: Country Analysis
7.3.1. Germany Carbapenem Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Drug Class
7.3.1.2.2. By Application
7.3.1.2.3. By Distribution Channel
7.3.2. France Carbapenem Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Drug Class
7.3.2.2.2. By Application
7.3.2.2.3. By Distribution Channel
7.3.3. United Kingdom Carbapenem Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Drug Class
7.3.3.2.2. By Application
7.3.3.2.3. By Distribution Channel
7.3.4. Italy Carbapenem Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Drug Class
7.3.4.2.2. By Application
7.3.4.2.3. By Distribution Channel
7.3.5. Spain Carbapenem Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Drug Class
7.3.5.2.2. By Application
7.3.5.2.3. By Distribution Channel
8. ASIA PACIFIC CARBAPENEM MARKET OUTLOOK
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Drug Class
8.2.2. By Application
8.2.3. By Distribution Channel
8.2.4. By Country
8.3. Asia Pacific: Country Analysis
8.3.1. China Carbapenem Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Drug Class
8.3.1.2.2. By Application
8.3.1.2.3. By Distribution Channel
8.3.2. India Carbapenem Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Drug Class
8.3.2.2.2. By Application
8.3.2.2.3. By Distribution Channel
8.3.3. Japan Carbapenem Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Drug Class
8.3.3.2.2. By Application
8.3.3.2.3. By Distribution Channel
8.3.4. South Korea Carbapenem Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Drug Class
8.3.4.2.2. By Application
8.3.4.2.3. By Distribution Channel
8.3.5. Australia Carbapenem Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Drug Class
8.3.5.2.2. By Application
8.3.5.2.3. By Distribution Channel
9. MIDDLE EAST & AFRICA CARBAPENEM MARKET OUTLOOK
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Drug Class
9.2.2. By Application
9.2.3. By Distribution Channel
9.2.4. By Country
9.3. Middle East & Africa: Country Analysis
9.3.1. Saudi Arabia Carbapenem Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Drug Class
9.3.1.2.2. By Application
9.3.1.2.3. By Distribution Channel
9.3.2. UAE Carbapenem Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Drug Class
9.3.2.2.2. By Application
9.3.2.2.3. By Distribution Channel
9.3.3. South Africa Carbapenem Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Drug Class
9.3.3.2.2. By Application
9.3.3.2.3. By Distribution Channel
10. SOUTH AMERICA CARBAPENEM MARKET OUTLOOK
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Drug Class
10.2.2. By Application
10.2.3. By Distribution Channel
10.2.4. By Country
10.3. South America: Country Analysis
10.3.1. Brazil Carbapenem Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Drug Class
10.3.1.2.2. By Application
10.3.1.2.3. By Distribution Channel
10.3.2. Colombia Carbapenem Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Drug Class
10.3.2.2.2. By Application
10.3.2.2.3. By Distribution Channel
10.3.3. Argentina Carbapenem Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Drug Class
10.3.3.2.2. By Application
10.3.3.2.3. By Distribution Channel
11. MARKET DYNAMICS
11.1. Drivers
11.2. Challenges
12. MARKET TRENDS & DEVELOPMENTS
12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments
13. GLOBAL CARBAPENEM MARKET: SWOT ANALYSIS
14. PORTER'S FIVE FORCES ANALYSIS
14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products
15. COMPETITIVE LANDSCAPE
15.1. Menarini Group
15.1.1. Business Overview
15.1.2. Products & Services
15.1.3. Recent Developments
15.1.4. Key Personnel
15.1.5. SWOT Analysis
15.2. Pfizer Inc.
15.3. Sun Pharmaceutical Industries Ltd
15.4. Lupin Limited
15.5. Kopran Limited
15.6. Aurobindo Pharma Limited
15.7. Daewoong Pharmaceuticals Co., Ltd.
15.8. Shenzhen Haibin Pharmaceutical Co. Ltd.
15.9. Merck & Co., Inc.
15.10. Venus Remedies Ltd.
16. STRATEGIC RECOMMENDATIONS
17. ABOUT US & DISCLAIMER
